NYSE:TRXC
Delisted

Transenterix Stock News

etoro logo Buy TRXC
*Your capital is at risk
$0.698
+0 (+0%)
At Close: Jul 20, 2022
Is (TRXC) Outperforming Other Medical Stocks This Year?
TRXC stock has potential to become the next Intuitive Surgical with its Senhance platform opening up a multi-billion dollar revenue stream The post TransEnterix Has A Compelling Case To Be The Next In

TransEnterix Announces New Training Center in EU

08:45am, Thursday, 18'th Feb 2021
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimal
TransEnterix is facing competition from a number of much larger companies, while its revenue is quite low. Investors should take profits on TRXC stock.
So, after contrasting the opportunities and risks with TRXC stock, what's the play? It may be interesting at lower prices.
TransEnterix is currently trading above $5. But does TRXC stock have what it takes to be the next Intuitive Surgical?
TRXC stock will do well over time, now that the company is well-capitalized. But does that mean it's a good time for new investors to hop on?
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimal
Is (TRXC) Outperforming Other Medical Stocks This Year?
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimal

Butterfly Floating Into Public Scene

05:37pm, Wednesday, 27'th Jan 2021
A firm named by FierceBiotech as one of the top merger and acquisition targets in medtech is going public via a special purpose acquisition company. Butterfly Network will become a wholly-owned subsid
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the
TransEnterix (TRXC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The robotic surgery specialist is helping to enhance the capabilities of surgeons, but its shares may have come too far, too fast.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE